Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesSitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation
Journal of Diabetes and its Complications, 10/29/09
White PC et al. – The observed increased rate of infection in diabetic patients treated with sitagliptin cannot be explained by a major effect on T–cell activation. Randomized studies, preferably using several assays of immune function, should be performed to confirm and extend these findings.
Related Articles
Sitagliptin 100mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
Current Medical Research and Opinion, 10/08/09
Relevance Score: 89%
FDA Approves Revisions to Prescribing Information for Diabetes Medications
American Family Physician, 11/06/09
Relevance Score: 87%
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
Diabetes, Obesity and Metabolism, 10/06/09
Relevance Score: 82%
Today in Endocrine...keeping you current
Receive free subspecialty "5-minute updates" via email
Bim-Mediated Apoptosis Is Not Necessary for Thymic Negative Selection to Ubiquitous Self-Antigens
Journal of Immunology, 12/11/09
Control of central self-tolerance induction by autoreactive CD4+ thymocytes
Trends in Immunology, 12/10/09
Autoimmune Regulator Deficiency Results in Decreased Expression of CCR4 and CCR7 Ligands and in Delayed Migration of CD4+ Thymocytes
Journal of Immunology, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor